Non‐serious adverse events: diarrhoea or abdominal pain, or both · people with cirrhosis and hepatorenal syndrome
It is very uncertain whether terlipressin changes non‐serious adverse events: diarrhoea or abdominal pain, or both compared with other vasoactive drugs (very low certainty).
1 finding from 1 review
RR 3.5 [1.19, 10.27]
221 participants
Very low
Non‐serious adverse events Timing of outcome assessment: end of treatment · patients with borderline personality disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Non‐serious adverse events · people with pressure ulcers
The intervention may leads to higher non‐serious adverse events (low certainty).
1 finding from 1 review
Non‐serious adverse events (secondary outcome) · prevention and treatment of hepatic encephalopathy in people with cirrhosis
It is very uncertain whether lactulose changes non‐serious adverse events (secondary outcome) compared with lactitol (very low certainty).
1 finding from 1 review
Non‐serious adverse events (secondary outcome) · prevention and treatment of hepatic encephalopathy in people with cirrhosis
It is very uncertain whether non‐absorbable disaccharides changes non‐serious adverse events (secondary outcome) compared with placebo/no intervention (very low certainty).
1 finding from 1 review
Non‐serious adverse events assessed using ICH‐GCP · people with cirrhosis who had minimal or overt hepatic encephalopathy or who were at risk for developing hepatic encephalopathy;…
It is very uncertain whether L‐ornithine L‐aspartate changes non‐serious adverse events assessed using ICH‐GCP compared with lactulose (very low certainty).
1 finding from 1 review
Non‐serious adverse events assessed using ICH‐GCP · people with cirrhosis who had minimal or overt hepatic encephalopathy or who were at risk for developing hepatic encephalopathy;…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Non‐serious adverse events assessed using ICH‐GCP · people with cirrhosis who had minimal or overt hepatic encephalopathy or who were at risk for developing hepatic encephalopathy;…
It is very uncertain whether L‐ornithine L‐aspartate changes non‐serious adverse events assessed using ICH‐GCP compared with rifaximin (very low certainty).
1 finding from 1 review
Non‐serious adverse events ‐ total number of participants · prevention and treatment of hepatic encephalopathy in people with cirrhosis
It is very uncertain whether summary of findings table ‐ Rifaximin changes non‐serious adverse events ‐ total number of participants compared with non‐absorbable disaccharide (very low certainty).
1 finding from 1 review
Non‐serious adverse events ‐ total number of participants · prevention and treatment of hepatic encephalopathy in people with cirrhosis
It is very uncertain whether summary of findings table ‐ Rifaximin plus non‐absorbable… changes non‐serious adverse events ‐ total number of participants compared with non‐absorbable disaccharides alone (very low certainty).
1 finding from 1 review
Non‐serious adverse events ‐ total number of particiapnts · prevention and treatment of hepatic encephalopathy in people with cirrhosis
It is very uncertain whether summary of findings table ‐ Rifaximin changes non‐serious adverse events ‐ total number of particiapnts compared with placebo/no intervention (very low certainty).
1 finding from 1 review
Intervention not reported
Non‐serious local adverse events (all included trials) ICH‐GCP 1997 · patients with preventing hepatitis A.
The intervention showed no clear difference in non‐serious local adverse events (all included trials) ICH‐GCP 1997 (low certainty).
1 finding from 1 review
Intervention not reported
Non‐serious local adverse events (low risk of bias) inactivated HAV vaccine ICH‐GCP 1997 · patients with preventing hepatitis A.
The intervention showed no clear difference in non‐serious local adverse events (low risk of bias) inactivated HAV… (high certainty).
1 finding from 1 review
Intervention not reported
Non‐serious systemic adverse events (low risk of bias) inactivated HAV vaccine ICH‐GCP 1997 · patients with preventing hepatitis A.
The intervention showed no clear difference in non‐serious systemic adverse events (low risk of bias) inactivated… (high certainty).
1 finding from 1 review
Intervention not reported
Non‐serious local adverse events (low risk of bias) live attenuated HAV vaccine ICH‐GCP 1997 · patients with preventing hepatitis A.
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Non‐serious systemic adverse events (all included studies) inactivated HAV vaccine ICH‐GCP 1997 · patients with preventing hepatitis A.
The intervention showed no clear difference in non‐serious systemic adverse events (all included studies)… (low certainty).
1 finding from 1 review
Intervention not reported
Non‐serious systemic adverse events (low risk of bias) live attenuated HAV vaccine ICH‐GCP 1997 · patients with preventing hepatitis A.
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Non‐serious local adverse events (all included studies) live attenuated HAV vaccine ICH‐GCP 1997 · patients with preventing hepatitis A.
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Non‐serious systemic adverse events (all included studies) live attenuated HAV vaccine ICH‐GCP 1997 · patients with preventing hepatitis A.
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Non‐serious adverse events · people with Duchenne muscular dystrophy and progressive respiratory decline
Idebenone showed no clear difference in non‐serious adverse events compared with placebo (low certainty).
1 finding from 1 review